COR-L 23/CPR

Analysis of acquired drug resistance, study of large cell carcinoma of the lung

Human Caucasian lung, large cell carcinoma

STR-PCR Data: Amelogenin: X
CSF1PO: 11
D13S317: 10,11
D16S539: 11,13
D5S818: 10,12
D7S820: 9
THO1: 9
TPOX: 8
vWA: 19

The cell line COR-L23/CPR is a drug-resistant variant of COR-L23 (Sigma Catalogue number. 92031919). The line was developed by growing the parent line in increasing concentrations of cisplatin. Cisplatin accumulation is reduced in COR-L23/CPR and cross resistance to melphalan and other platinum compounds has been found. Cells tend to grow in clumps.

RPMI 1640 + 2mM Glutamine + 0.05μg / ml Cisplatin + 10% Foetal Bovine Serum (FBS).

Split sub-confluent cultures (70-80%) 1:2 to 1:5 i.e. seeding at 2-5 x 10,000 cells / cm² using 0.25 % trypsin or trypsin/EDTA; 5% CO₂; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.